Abstract

Making decisions on lipid-lowering treatment varies across Europe. Legislation differs from country to country, so it is difficult to generalize about European policy. From the perspective of the United Kingdom, this paper addresses the impact of rationing, cost containment, information feedback, fund-holding and drug expenses. Primary versus secondary prevention for cardiovascular disease is also discussed, including current recommendations for prescribing statins and other interventions.